Glenmark Pharmaceuticals Limited

rs,

May 23, 2025 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi

17.6%

in 45+ markets globally Glenmark’s Europe business continued its strong performance, growing at 17.6% for FY25 IGI presented first-time safety and efficacy data from its Phase 1 (Part 1) study of ISB

Rs. 32,562

uticals Ltd. All Rights Reserved Q4 FY25 Summary Consolidated Revenue • Consolidated Revenue of Rs. 32,562 Mn • YoY growth of 6.3% Regional Highlights • Europe Business YoY growth of 19.9% • ROW Business

6.3%

d Q4 FY25 Summary Consolidated Revenue • Consolidated Revenue of Rs. 32,562 Mn • YoY growth of 6.3% Regional Highlights • Europe Business YoY growth of 19.9% • ROW Business YoY growth of 4.9% “Ou

19.9%

venue of Rs. 32,562 Mn • YoY growth of 6.3% Regional Highlights • Europe Business YoY growth of 19.9% • ROW Business YoY growth of 4.9% “Our performance reflects the underlying resilience of our busin

4.9%

h of 6.3% Regional Highlights • Europe Business YoY growth of 19.9% • ROW Business YoY growth of 4.9% “Our performance reflects the underlying resilience of our business, the strength of our diversi

Rs. 5,607

tion-led pipeline continues to gain momentum, with Ichnos Glenmark Innovation (IGI) • EBITDA at Rs. 5,607 Mn, with EBITDA margin of receiving US FDA Fast Track designation for ISB 2001 — a Profitability

17.2%

, with EBITDA margin of receiving US FDA Fast Track designation for ISB 2001 — a Profitability 17.2% • Adjusted PAT1 at Rs. 3,466 Mn with Adjusted PAT margin of 10.6% significant milestone in our

Rs. 3,466

receiving US FDA Fast Track designation for ISB 2001 — a Profitability 17.2% • Adjusted PAT1 at Rs. 3,466 Mn with Adjusted PAT margin of 10.6% significant milestone in our journey towards advancing cutti

10.6%

ISB 2001 — a Profitability 17.2% • Adjusted PAT1 at Rs. 3,466 Mn with Adjusted PAT margin of 10.6% significant milestone in our journey towards advancing cutting- edge biologics for cancer care. T

Rs. 2,367

nts and reinforces our commitment to being a science-led, Other Highlights • R&D Expenditure of Rs. 2,367 Mn (7.3% of revenue) future-ready organization.” Glenn Saldanha Chairman and Managing Director Gle

7.3%

rces our commitment to being a science-led, Other Highlights • R&D Expenditure of Rs. 2,367 Mn (7.3% of revenue) future-ready organization.” Glenn Saldanha Chairman and Managing Director Glenmark Ph